PMID- 16541964
OWN - NLM
STAT- MEDLINE
DCOM- 20060801
LR  - 20161020
IS  - 1088-5412 (Print)
IS  - 1088-5412 (Linking)
VI  - 26
IP  - 6
DP  - 2005 Nov-Dec
TI  - What is new in antiimmunoglobulin E asthma therapy.
PG  - 428-34
AB  - Omalizumab, a recombinant humanized monoclonal antibody, is the first therapeutic 
      agent specifically targeting immunoglobulin E (IgE). It has been investigated 
      extensively in the treatment of patients with allergic diseases and is approved 
      in the United States for the treatment of patients with moderate-to-severe 
      persistent asthma. In this setting, omalizumab reduced the frequency and 
      incidence of asthma exacerbations and asthma control was well maintained, even 
      though patients significantly reduced their dose of inhaled corticosteroid. 
      Importantly, omalizumab has been shown to reduce asthma exacerbations in 
      high-risk patients (e.g., with previous intubation and hospitalization) and to 
      reduce the level of severe asthma exacerbations (those resulting in emergency 
      treatment and hospitalization). Responder analysis shows that omalizumab provides 
      the greatest benefit in patients with more severe asthma, and this has been 
      confirmed by recent studies establishing the efficacy of omalizumab in patients 
      whose asthma is poorly controlled despite receiving the best standard care in 
      medication. Omalizumab also has proved to be effective in patients with seasonal 
      and perennial allergic rhinitis and to improve quality of life for patients with 
      asthma or rhinitis. As expected with a systemic anti-IgE agent, omalizumab was 
      shown to be effective in the treatment of patients with concomitant asthma and 
      allergic rhinitis. The efficacy of omalizumab in a range of allergic diseases 
      reaffirms the importance of IgE in the pathogenesis of these conditions and 
      establishes the potential benefit to be obtained by inhibiting IgE, especially in 
      patients with more severe and comorbid allergic diseases.
FAU - Berger, William E
AU  - Berger WE
AD  - Allergy and Asthma Associates, Mission Viejo Medical Center, Mission Viejo, 
      California 92691, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Asthma/*drug therapy
MH  - Humans
MH  - Immunoglobulin E/*immunology
MH  - Omalizumab
MH  - Rhinitis, Allergic, Perennial/drug therapy
RF  - 48
EDAT- 2006/03/18 09:00
MHDA- 2006/08/02 09:00
CRDT- 2006/03/18 09:00
PHST- 2006/03/18 09:00 [pubmed]
PHST- 2006/08/02 09:00 [medline]
PHST- 2006/03/18 09:00 [entrez]
PST - ppublish
SO  - Allergy Asthma Proc. 2005 Nov-Dec;26(6):428-34.